I agree possible investigation sounds weak and the problem is that they have allowed this type of article filled with half truths by their own foolish actions. I don't think much will come from this, but the question is why did shorts need to hit the stock now? What are they afraid of? Hmmm.
according to some investors here, peak will be much higher than $3.2 at peak. Start with replacement of Herceptin, then add additional indications, then add premium pricing, could be more like $6-10BB at peak.
as did I, this shyte is really getting OLD. Management is enabling this through insider selling and focus on personal/exec/insider wealth creation over shareholders.
I agree, I am tempted to load up on call options after these desperate attempts to smear ARNA, although I was very angry about the rat cancer study blindside after asking them a very specific question regarding animal safety studies before the information came out, but I am over it now, just get the price up!
IMGN cant get lift off. BB's buying more SGEN. IMGN needs a respected large investor, activist, or insider buying (sure), something to boost confidence, or remove weak leadership and unleash the full value!
I really hate to agree with AF, but I would not touch MNKD at this level. $4BB market cap, huge debt, inhaled insulin was a commercial failure the first time, even Pfizer could not market it successfully. I usually disagree with AF. He has been wrong so far on MNKD and many others, but in the long run I agree MNKD is over-priced. Back to ARNA, which is not over-priced, but testing my patience!
again false. Total spending is not even $30MM/qtr and they have income of $5MM per quarter and growing. They can easily cut costs, or partner programs if needed, if Belviq revs ramp more slowly than expected. I am sure JL is well informed about shareholder disdain for additional dilution.
ARNA is not going to burn $160MM in a year, read the BS and IS if you are able then go back to basher class and try another angle, or get a real job. Bashing is not a real job, adds no value to society.
Excerpts from an article link found on Investor Village- Conclusions: Our results indicate that targeting HER-2 with T-DM1 may offer a new therapeutic approach in HER-2 over-expressing lung cancers including those resistant to EGFR TKIs. Article state between 2 and 20% of NSCLC pts. over-express HER2. That's a large potential new market. TDM1 is going to be huge, the only question is when and how much of that huge $ amount will IMGN receive under their contract.
IMGN sum of the parts are worth far more than the current value. Roche and Sanofi should offer to buy IMGN with Roche taking T-DM1 and Sanofi taking their drugs. Maybe SGEN will take the internal pipeline that IMGN can't seem to advance and AMGN, LLY, BT can bid on their own drugs. IMGN is way undervalued and investor/owners are getting tired of waiting for a return!
Howard Pien, and IMGN board member stepped in to turn around and sell MEDX in a similar situation, despised CEO, angry investors, undervalued stock, etc. Is IMGN a MEDX 2.0? I think so!
all our money??? You must know something that is not reflected in the current stock price...
IMGN is taking far too long to determine max dose and optimal dosing schedules. They need a new leader, DJ has lost credibility. Hit the road Dan, you have done well financially and the shareholders have not and demand change!
agreed, for biotech the presentations are usually fluff and the meat is always in the Q&A. As another poster pointed out stability for a small molecule should not be an issue. Stability was not a problem for ARNA's 5h2c drug Belviq.
Puma's trial results in BC were very weak and the company is still valued at almost 2x IMGN. Tykerb did not enhance Herceptin. News in FierceBiotech.
Interesting, I have a new, local idea for him...